Serum MCP-1 (CCL2), MCP-2 (CCL8), RANTES (CCL5), KI67, TNF-β levels in patients with benign and borderline ovarian tumours

Objective: The purpose of this study was to assess, among others, monocyte chemoattractant protein type-1 MCP-1 [also called chemokine ligand 2 (CCL2)], MCP-2 (CCL8), regulated on activation, normal T cell expressed and secreted (RANTES) (CCL5), Ki-67, and transforming growth factor beta (TNF-β) levels in the serum of patients with benign and borderline ovarian lesions. Study Design: Patients who underwent laparoscopy and or laparotomy in the Gynecology and Obstetrics Clinical Hospital, Poznan Medical University, Poland, for adnexal changes in the form of endometrial cysts (n=11) and mature teratomas (n=11), mucinous cysts (n=16), borderline tumors of the ovary (n=17), simplex (serosa) cysts (n=19), or hemorrhagic cysts (n=5) were included in this study. Results: The differences in the medians of MCP-1, MCP-2, RANTES, Ki-67, and TNF-β were non-statistically significant. Spearman’s correlation analysis performed on the group of women with endometriomas showed a statistically significant and positive dependence on the level of RANTES with Ki-67 (r = 0.6; p = 0.0467). Moreover, Spearman’s correlation analysis performed on the group of women treated surgically for mature teratomas was statistically significant for the level of MCP-1 with TNF-β (r = 0.7; p = 0.0301). Conclusion: The study of serum levels of MCP-1 (CCL2), MCP-2, RANTES (CCL5), Ki-67, and TNF-β in patients with benign and borderline ovarian tumors revealed correlations between the level of RANTES and Ki-67 and of MCP-1 and TNF-β, which suggests that chemokines as the markers of benign and borderline ovarian tumors are questionable.

MCP-1 (CCL2); MCP-2; RANTES (CCL5); KI67; TNF-β; Benign ovarian tumor; Borderline ovarian tumor

[1] Agic A., Xu H., Finas D., Banz C., Diedrich K., Hornung D.: “Is Endometriosis Associated with Systemic Subclinical Inflammation?” Gynecol. Obstet. Invest., 2006, 62, 139.

[2] Barton-Smith P., Ballard K., Kent A.S.H.: “Endometriosis: a general review and rationale for surgical therapy”. Rev. Gynaecol. Perinat. Pract., 2006, 6, 168.

[3] Bal J., Gabryś M.S., Jałocha I.: “The role of selected molecular pathways in the pathogenesis of ovarian teratomas”. Postepy. Hig. Med. Dosw., 2009, 63, 242.

[4] Sikora-Szczęśniak D., Sikora W.: “Fertility sparing surgical treatment of malignant ovarian tumors in the reproductive age group of women“. Ginekol. Pol., 2012, 83, 27.

[5] Giurgea L.N., Ungureanu C., Mihailovici M.S.: “The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors”. Rom. J. Morphol. Embryol., 2012, 53, 967.

[6] Gołąb J., Jakóbisiak M., Zagożdżon R., Obłąkowski P.: “Cytokiny”. In: Gołąb J., Jakóbisiak M., Lasek W. (eds). Immunology. Warsaw: PWN, 2006, 198.

[7] Chmaj-Wierzchowska K., Kampioni M., Wilczak M., Sajdka S.: “Plasma fibrinogen, CRP and hs-CRP levels in patients with benign and borderline ovarian tumours”. Eur. J. Gynaecol. Oncol. [In press].

[8] Carr M.W, Roth S.J, Luther E., Rose S.S., Springer T.A.: “Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant”. Proc. Natl. Acad. Sci., U.S.A., 1994, 91, 3652.

[9] Xu L.L, Warren M.K, Rose W.L, Gong W., Wang J.M.: “Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro”. J. Leukoc. Biol., 1996, 60, 365.

[10] Conti I., Rollins B.J.: “CCL2 (monocyte chemoattractant protein-1) and cancer”. Semin. Cancer. Biol., 2004, 14, 149.

[11] Wang L., Zheng W., Zhang S., Chen X., Hornung D.: “Expression of monocyte chemotactic protein-1 in human endometrial cancer cells and the effect of treatment with tamoxifen or buserelin”. Int. J. Med. Res., 2006, 34, 284.

[12] Gong W., Howard O.M., Turpin J.A., Grimm M.C., Ueda H., Gray P.W., et al.: “Monocyte chemotactic protein-2 activates CCR5 and blocks CD4/CCR5-mediated HIV-1 entry/replication”. J. Biol. Chem., 1998, 273, 4289.

[13] Proost P., Wuyts A., Van Damme J.: “Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1”. J. Leukoc. Biol., 1996, 59, 67.

[14] Arici A., Senturk L.M., Seli E., Bahtiyar M.O., Kim G.: “Regulation of monocyte chemotactic protein-1 expression in human endometrial stromal cells by estrogen and progesterone”. Biol. Reprod., 1999, 61, 85.

[15] Tao Y., Zhang Q., Huang W., Zhu H., Zhang D., Luo W.: “The peritoneal leptin, MCP-1 and TNF-α in the pathogenesis of endometrio- sis-associated infertility”. Am. J. Reprod. Immunol., 2011, 65, 403.

[16] Gmyrek G.B., Sozanski R., Jerzak M., Chrobak A., Wickiewicz D., Skupnik A., et al.: “Evaluation of monocyte chemotactic protein-1 levels in peripheral blood of infertile women with endometriosis”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2005, 122, 199.

[17] Hefler L., Tempfer C., Heinze G., Mayerhofer K., Breitenecker G., Leodolter S., et al.: “Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients“. Br. J. Cancer, 1999, 81, 855.

[18] Falcão-Júnior J.O., Teixeira-Carvalho A., Cândido E.B., Lages E.L., Ferreira Freitas G. G., Lamaita R.M., et al.: “Assessment of chemokine serum levels in epithelial ovarian cancer patients”. Tumori., 2013, 99, 540.

[19] Wei X., Tian Y., Lu W., Li W., Zhang M., Lu X., Liu Y.: “Functional polymorphisms in monocyte chemoattractant protein-1 are associ- ated with increased susceptibility to ovarian cancer”. DNA Cell. Biol., 2015, 34, 37.

[20] Kristjánsdóttir B., Partheen K., Fung E.T., Yip C., Levan K., Sundfeldt K.: “Early inflammatory response in epithelial ovarian tumor cyst fluids”. Cancer Med., 2014, 3, 1302.

[21] Kyama C.M., Debrock S., Mwenda J.M., D’Hooghe T.M.: “Potential involvement of the immune system in the development of endometriosis”. Reprod. Biol. Endocrinol., 2003, 1, 123.

[22] Laudański P., Szamatowicz J., Oniszczuk M.: “Profiling of peritoneal fluid of women with endometriosis by chemokine protein array”. Adv. Med. Sci., 2006, 51, 148.

[23] Margari K.M., Zafiropoulos A., Hatzidaki E., Giannakopoulou C., Arici A., Matalliotakis I.: “Peritoneal fluid concentrations of β-chemokines in endometriosis”. Eur J. Obstet. Gynecol. Reprod. Biol., 2013, 169, 103.

[24] Tsukishiro S., Suzumori N., Nishikawa H., Arakawa A., Suzumori K.: “Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder”. Gynecol. Oncol., 2006, 102, 542.

[25] Henzen-Logmans S.C., Fieret E.J., Berns E.M., van der Burg M.E., Klijn J.G., Foekens J.A.: “Ki-67 staining in benign, borderline, ma- lignant primary and metastatic ovarian tumors: correlation with steroid receptors, epidermal-growth-factor receptor and cathepsin D”. Int. J. Cancer., 1994, 57, 468.

[26] Plewka D., Kowalczyk A.E., Jakubiec-Bartnik B., Morek M., Bogunia E., Kmiec A., Wierzbicki P.M., Plewka A.: “Immunohistochemical visualization of pro-inflammatory cytokines and enzymes in ovarian tumors”. Folia. Histochem. Cytobiol., 2014, 52, 124.